Well on track 2023年财报简评：持续输出爆款，连续四季度运营利润为正利 FY2023Q2业绩点评：经调净利润+74%yoy，国内疫情下业绩仍超预期 Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL 4Q22 miss; 5 new models in the next 5 months 调整2023-24E预测及目标价；维持“持有”评级 Evolving to a self-sustained business model 2022Q4业绩点评：进入有质量增长时代 首次实现全年运营盈利，原创内容生产进入良性循环 年报点评报告：单季实现盈利 市场份额有望持续扩大